Evidence map›Paper›PMID 39590604›Full record

ArticleJournal of personalized medicine2024

The Effects of Mepolizumab on CRSwNP: Real-Life Evidence.

Elena Cantone, Bernardino Cassiano, Paolo Pezzella, Mario Brandon Russo, Aikaterini Detoraki, Path2 Federico II Task Force

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Efficacy and safety of mepolizumab in the treatment of CRSwNP in the real-life setting: a review of the literature.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Review
  2. Mepolizumab reduces healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps: a linked EMR and claims-based pre-post study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026
    Article
  3. Short-term effectiveness of tezepelumab on ENT manifestations in patients undergoing treatment for severe asthma: A pilot real-life study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Observational
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elena CantoneDepartment of Neuroscience, Reproductive Sciences and Dentistry, University of Naples "Federico II", 80138 Naples, Italy.ORCID 0000-0002-7389-2033
Bernardino CassianoUOSD di Otorinolaringoiatria, ASL Napoli 3, Ospedale di Nola, Via delle Repubbliche 7, 80035 Nola, Italy.
Paolo PezzellaDepartment of Neuroscience, Reproductive Sciences and Dentistry, University of Naples "Federico II", 80138 Naples, Italy.ORCID 0009-0005-7237-2641
Mario Brandon RussoDepartment of Engineering, University of Campania "Luigi Vanvitelli", 81031 Aversa, Italy.ORCID 0000-0002-9029-8191
Aikaterini DetorakiDivision of Internal Medicine and Clinical Immunology, Department of Translational Medical Sciences, University of Naples "Federico II", 80138 Naples, Italy.ORCID 0000-0002-3692-1384
Path2 Federico II Task Force

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-IL5asthmabiologicsCRSwNPnasal polypsolfactionQoLVAS

Identifiers

PMID39590604
PMCPMC11595308

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.